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THE description of a line of transplanted mammary fibroadenomata in rats
was presented in a preceding paper from this laboratory (Millar and Noble, 1954).
Observations by us and others have shown that this type oftumour is more easily
propagated, grows more rapidly and usually shows greater epithelial development
in the female host than in the male. In addition, castration in males and females
increases and decreases respectively the growth energy oftransplanted mammary
fibroadenomata in rats. In order to elucidate further the nature ofthe hormonal
control of these benign tumours, experiments have been carried out to determine
the effect ofadministered pituitary, adrenal and sex hormones on their growth and
morphology.
The effect of estrogens on the growth of mammary fibroadenomata in rats
has been studied by several workers with somewhat conflicting results. Heiman
and Krehbiel (1936) found no consistent tumour response to administered estro-
gens. However, estrogen (theelin) plus growth hormone (Antuitrin S) or gonado-
trophic hormone (Antuitrin G) increased the number of tumour takes in intact
rats, although none of the individual preparations were active. Antuitrin S
alone was effective in increasing the takes in castrated males and females, while
estrogen and growth hormone were again effective only when injected simultane-
ously. In these experiments tumours ofthe 13th to 22nd generations were used.
Estrogenadministrationto ratsbearingauto- andhomo-transplants ofspontaneous
tumours produced marked tumour epithelial proliferation and increased growth
rate (Heiman, 1940b).
Mohs (1940) found that injections ofestrogen to castrated rats implanted with
fibroadenoma tissue, increased the number oftakes in both sexes andincreased the
tumour growth-rate in female castrates. The tumour lines used by this author
were in the first to third transplanted generation. These results, reviewed with
those ofHeiman etal., suggestthat thefibroadenoma maybecome lessresponsiveto
exogenous estrogens in the later generations of a tumour line.
Emge and co-workers found no change in the growth characteristics or morpho-
logy of transplanted fibroadenomata with long continued administration of from
50 i.u. bi-weekly to 200 i.u. daily of theelin (Emge, Murphy and Shilling, 1938;
Murphy, Shilling and Emge, 1938; Emge and Murphy, 1938). However, largerM. JEAN MILLAR AND R. L. NOBLE
doses-up to 1000 i.u. oftheelin daily-administered for shorter periods, produced
progressive hyperplastic changes in the epithelium of the tumour, ending in
fibrosis (Emge, 1939). The aim of the work reported in these papers was to
determine whether excess estrogen would be instrumental in initiating a malignant
change in the epithelium of the benign mammary fibroadenomata in rats. No
such effect was indicated.
Heiman (1940a, 1943) has reported that administered testosterone proprionate
or progesterone caused a marked reduction of tumour takes and a depression of
epithelial development. Testosterone also decreased the tumour growth-rate.
These two hormones injected simultaneously effected a greater reduction of takes
than either alone. Pregnancy or simultaneous injections of estrogen could offset
the inhibitory action ofeither progesterone or testoterone. Mohs (1940) found no
growth inhibition oftransplanted fibroadenomata in castrated rats receiving small
doses of testosterone, but later reported (Mohs, 1941) that such tumours changed
to pure fibromata after 25 weeks oftreatment.
METHODS.
The transplantation technique and procedure for obtaining and evaluating
the results on tumour growth are given in detail in the first paper (Millar and
Noble, 1954). In brief, tumour areas, determined weekly, were plotted against
time to obtaingrowth curves. Threecriteriawereusedto demonstrate aresponse,
i.e., the number of tumour takes, the latent period and the tumour" growth-
rate." The latent period was described as the time lapse between the tumour
implantation date and the time the implant had reached a size of 0.4 square
inches. An arbitrary "growth period" designated as the time for the tumour
to grow from 0.4 to 3.0 square inches served to describe the growth rate. Mean
tumour latent and growth periods for treated and control groups were compared
by the " t " test of Fisher, using a probability of 0.05 as the level of significance.
All means will be presented with their Standard Errors
The tumour line (F) described in the previous paper was used for most ofthe
work to be outlined. Two additional lines (3 F and 4 F) have been used in a few
experiments. The transplant generation is designated by the number following
the letter F (i.e., 3 F3). Young adult Sprague-Dawley rats were used throughout.
The age ofrats for each transplant series was the same.
In general, two treatment regimes were used. Unless treatment was started
after tumour growth initiation, rats were injected during the first, third and
fourth, or fourth and fifth weeks after tumour tissue implantation, or continu-
ously from the implantation date until the death ofthe animal. The former will
be called "limited ", the latter "continuous" treatment. Limited treatment
was employed in the early work with the F tumour line. This regime was
based on an expected latent period ofapproximately 4 weeks, and the assumption
that the first weeks' treatment would affect the establishment of tumour implant
and the latter 2 weeks treatment, the initiation ofgrowth and possibly the growth
rate. However, the occurrence of tumours with prolonged latent periods made
this plan unfeasible and continuous treatment was adopted for later experiments.
The results will be presented in separate sections dealing with the various
hormone preparations used for treatment, and particulars regarding dose levels,
etc., will be included in each.
496EXOGENOUS HORMONES AND RAT MAMMAIARY FIBROADENOMA
RESULTS.
(1) Effect of estrogens.
The effect ofestrogens was determined for " low "(1 to 10,tg. daily) and" high"
(50 to 200 ,u.g daily) dose levels. In all but one experiment, where estradiol
benzoate was used, the synthetic estrogen diethylstilbestrol was employed.
(a) Low dose levels.-Seven individuals experiments were carried out to deter-
mine the effect of low doses of estrogen on the growth of transplanted mammary
fibroadenomata in female rats (Series F3, F4-B, F5-A, F5-C, F6, 3 F3 and 4 F3).
"Limited" treatment was employed in all but Series 3 F3 and 4 F3. The estro-
gen was injected subcutaneously in a 5 or 10 per cent ethyl alcohol solution.
Tumour growth stimulation by estrogen was indicated in Series F3 only, since the
number of takes was higher and the latent period significantly decreased.
Table I shows results for Series F3 and F6, the latter being representative of
the negative groups.
TABLE I.-Effect of Low Doses of Diethylstilbestrol on the Growth of Transplanted
Fibroadenomata in Female Rats.
Daily Number Number Mean latent Mean growth
dose of of period period
Series. Treatment. (,g.). rats. takes. (days). (days).
F3 Stilbestrol, limnited 5 6 . 6 37±2 .6* 42±6-0
Controls - 6 . 3 . 60 ±10 3 39i 1 8
F6 Stilbestrol, limited . 10 8 7 . 27± 2-7 . 41±1-1
Controls . - 10 . 9 . 43 15 4 35+3 2
* Treated versus controls, P < 0 05.
Negative tumour response occurred despite alterations in the dose level (1 5 and
10 ,ug. daily), the type of estrogen used, diethylstilboestrol or estradiol benzoate,
and the duration of treatment.
Estrogen treatment did not appear to alter the morphology ofthe fibroadeno-
mata in female rats.
The effect of small doses of estrogen on the growth and morphology of these
benign tumours was studied also for male rats, using both limited and continuous
treatment. (Series F4-A, FS and F-9-A.) Table II gives the growth results
obtained.
Although the results in Series F4-A did not differ significantly from the male
controls, there was an indication of response in the shorter mean latent period of
treated rats. This is more obvious when the individual values are observed for
this determination. They were for treated and control tumours, 86, 110, 89 and
219, 136, 133 days respectively. The high degree of significance obtained for the
difference between treated and control males in Series F8 confirms the earlier
indications. The trend is again evident in Series F9-A, although the results were
not statistically significant.
Histologically, enhanced epithelial development was evident in the tumours of
continuously treated rats. The majority of these tumours presented the appear-
ance of the "typical" fibroadenoma as described by Millar and Noble (1954).
In untreated males the connective tissue stroma was more predominant.
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TABLE II.-Low Doses ofDiethylstilbestrol on the Growth ofTransplanted Mammary
Fibroadenomata in Male Rats.
Number Number Mean latent Mean growth
of of pbriod period
Series. Treatment. rats. takes. (days). (days).
F4-A . Stilbestrol, limited* . . 8 . 3 . 95± 7-5 . 105+16-6
Control, male . . 8 . 3 . 163+28.2 . 764- 60
Control, female . 8 . 6 64±i14-0 . 95+296
F8 . Stilbestrol, continuoust . 10 . 8 . 32i 0- 7 . 24+ 0 7
Control, male . . . 10 . 10 . 45± 3-4 . 32± 1-6
Control, female . . 10 . 10 . 37 4-4 . 27± 2 7
F9-A Stilbestrol, continuous* . 10 . 7 . 43i 44 59±15-6 Control, male . . . 10 . 8 . 58±i 6-5 . 63+11-7
Control, female . 10 . 7 . 41± 4-6 . 35i 2- 1
* Stilbestrol, 5 [,g. daily.
t Stilbestrol, 10 [g. every second day.
P < 0.01, treated versus male controls.
(b) High doses of Estrogen.-In the experiments to be described, diethylstil-
bestrol was administered by subcutaneous injection dissolved in sesame oil or
orally as a constituent of the drinking water (0.5 mg. per cent solution).
Early experiments (Series F4-B and F6), using the "limited" treatment period,
indicated that a daily dose of 100 ,tg. of diethylstilbestrol (by injection) could
delay tumour growth initiation, although significant increases in the mean latent
periods were not observed. The trend was substantiated by following experi-
ments in which the treatment period was extended until after tumour growth was
well established in the control groups (Series F9-A, F12, 4F3). For both males
and females, no tumour growth occurred during the treatment period and for
some weeks after injections were discontinued. Table III gives the data for a few
representative experiments.
TABLE III.-Effect of High Doses of Diethylstilbestrol Injected from the Time of
Tumour Implantation on the Growth of Transplanted Fibroadenomata in Rats.
Number Number Mean latent Mean growth
of of period period Series. Treatment. Sex. rats. takes. (days). (days).
F9-A . Stilbestrol* . F 10 7 123± 4- .3 . 49± 70
Controls . . F . 10 . 7 41± 3-6 . 35± 20
Stilbestrol* . M . 10 . 6 151±10.6:t . 53± 64
Controls . . M 10 . 8 . 59± 6-5 . 6311-5
F12 . Stilbestrolt
. F 7 4 101± 7-7t
. 38± 3 -2
Controls . . F . 10 7 42± 6-1 . 39+3 -9
* Stilbestrol, 400 ,ug. every 2nd day for 52 days after tumour implantation.
t Stilbestrol, 200 [,g. every 2nd day for 58 days after tumour implantation. I P < 0- .01, treated versus controls.
When administered orally in the drinking water, the daily consumption of
diethylstilbestrol was approximately 50 ,ug. In neither females or males was this
amount sufficient to delay the initiation of tumour growth. However, for the
females (Series F6) tumour growth was arrested or slowed in 5 of 8 tumour-
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bearing rats. The remaining 3 tumours appeared unaffected. The mean growth-
period for this group was significantly longer than the controls.
The growth results for male rats were less easily evaluated. Two groups
of
8 rats in the same series (Series F8) received diethylstilbestrol orally. One of
these groups received, in addition, injections of a crude beef anterior pituitary
preparation (to be described in a later section). Only 2 out of 8 tumours in the
group receiving stilbestrol alone showed growth retardation, while the growth
rate was markedly reduced in 6 of 8 tumours of the group receiving both estrogen
and the anterior pituitary preparations. Since, as it will be shown, the anterior
pituitary preparation alone can stimulate the growth of mammary fibro-
adenomata in male rats, it was considered unlikely that this product produced
an additive inhibiting action with high doses of diethylstilbestrol. Rather, in
view ofthis consideration and the apparent all or none action of diethylstilbestrol
when administered at this dose level, the unequal response of these two groups
has been attributed to change variation alone. Therefore, the results from these
two groups have been pooled and presented as a single group. In this case the
mean growth period of the tumours of treated rats was significantly longer than
the controls, as may be seen from Table IV.
TABLE IV.-Effect of High Doses of Diethylstilbestrol administered Orally from the
Time of Tumour Implantation on the Growth of Transplanted Fibro-
adenomata in Rats.
Number Number Mean latent Mean growth
of of period period
Series. Treatment.* Sex. rats. takes. (days). (days).
F6 Stilbestrol (continuous) F 8 8 31± 3-4 113±25-4
Controls F 10 9 43±154 35 3 2
F8
.
Stilbestrolt
. . . M . 20 . 515100 79413
Controls M 10 450 34 32010 .6
Drinking water 0- 5 mg. per cent diethylstilbestrol,
approximate daily intake 50 ,ug.
t Stilbestrol, administered for 168 days after tumour implantation.
4 P < 0.01, treated versus controls.
IP < 0 05, treated versus controls.
Finally, experiments were undertaken to determine the effect of high doses of
estrogen on already growing tumours. Rats in two series (FS5-B and F12) were
injected with stilbestrol after the tumours had reached a size of approximately 0.5 square inches. Treatment for 3 weeks (100 ,ug. stilbestrol daily) caused
little change in tumour growth rate (Series F5-B). In Series F12 tumour-
bearing rats were injected every second day for 60 days with 200,g. ofdiethyl-
stilbestrol. Tumour growth was arrested in 4 rats, while there was no response
in the remaining 3. Since some of these animals died before the tumours reached
3 square inches, it was not possible to calculate a mean growth period for this
group. The results are presented, therefore, in Fig. 1, which shows tumour areas
plotted against time for each tumour in the treated group. As the retarded
tumours didnot exhibit a rapid recovery after the cessation of treatment, it cannot
be ruled out that the tumour growth trend was independent of the treatment.
However, no such slow growing tumours occurred in the controls (mean growth
period 39
i 3-9 days) or any other group in this series, a fact which favours the
499M. JEAN MILLAR AND R. L. NOBLE
Cd
ca
S..
0
E-
Time in davs
FIG. 1.-Effect of high doses of diethylstilbestrol on growing
fibroadenomata in rats (Series F12).
interpretation that the estrogen was at leastpartially responsiblefor the depressed
growth of these tumours.
Estrogens administered at the high dose levels given cause considerable body
growth retardation and occasionally incur the death ofthe animal. It was neces-
sary, therefore, to determine whether tumour growth inhibition was merely
concurrent with body growth depression or whether it could be attributed more
specifically to the estrogen administered. It has been reported (Millar andNoble, 1952) that dietary restriction sufficient to cause body growth depression equal to
that observed in stilbestrol treated rats (100 /g. daily) had little or no effect on
the growth initiation of fibroadenoma implants, or on the tumour growth rates.
In addition, the initiation oftumour growth after cessation ofstilbestrol injections
(treatment started at time of tumour implantation) could not be delayed further
by dietary restriction, sufficient to prevent the host from recovering from the body
weight depressing effects of this hormone.
There didnotseemto be anyalterationinthedistribution ofthebenignvariants
of the fibroadenoma in animals treated with high doses of stilbestrol. The inci-
dence offibrosarcomata was unaltered also in these groups, where tumour growth
initiation did not occur till after treatment was discontinued. However, for those
animals which received stilbestrol during tumour growth there was an increase
in the number of sarcomatous transformations, this event being restricted to
tumours whose growth had been arrested or retarded during the treatment. The
results for female rats are given in Table V.
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TABLE V.-Effect of High Doses of Diethylstilbestrol Administered During Tumour
Growth on the Incidence of Fibrosarcomnata in Female Rats.
Benign
Group. tumours. Fibrosarcomata.
Treated (13 rats) . . 5 . 8
Controls (19 rats) . . . 17 2
X2 test, P < 0.01.
According to the X2 test there is a significant difference in the incidence of
fibrosarcomata in the treated and conrtrol groups. This data includes the groups
receiving stilbestrol byinjection after tumourgrowth initiation and those receiving
diethylstilbestrol orally from the time of tumour implantation. The latter
groups are included since the treatment period extended well after tumour growth
initiation.
With regard to male rats on this regime (Series F8) the results were less con-
clusive. Eight of 16 tumours became sarcomatous in the treated group, and
again, this change was restricted to those tumours showing retarded or arrested
growths. However, 3 of 6 tumours in the controls became sarcomatous. It
would appear, therefore, that tumours in the male rats ofthis series were initially
more predisposed to become fibrosarcomata, since in the control group the sarco-
matous tumours were fairly fast growing and showed a tendency to fibrous tissue
development while in the benign state.
(2) Effect ofprogesterone.
Experiments were conducted with female rats in which progesterone was
injected alone (5 mg. daily) or with low doses ofestrogen for the "limited" treat-
ment period (Series F4-B and F5-C). No change was observed in the growth
characteristics or morphology of the tumours oftreated rats.
(3) Effect of androgen.
Testosterone proprionate injected into female rats forthe "limited "treatment
period (1 mg. daily) did not affect the growth or morphology of fibroadenoma
implants (Series F4-B and F5-C). However, when the duration oftreatment was
extended (106 days after tumour implantation) there was an indication of slight
tumour growth inhibition (Series F10-A and Fll ). Due to the death of some
animals before the tumours had reached 3'0 square inches, mean growth periods
could not be calculated.
Data regarding tumour morphology was scant, but there was a trend towards
increased fibrous tissue development in the tumours of testosterone treated rats.
The results in this section are inadequate for any independent conclusions to
be drawn. However, when considering the findings of Heiman and Mohs for the
action of androgens on the fibroadenoma which were outlined earlier, the trends
observed may be significant.
(4) Effect ofcortisone.
One experiment in Series F5-B was carried out to determine the effect of
cortisone on transplanted fibroadenomata in female rats. Cortisone acetate in
aqueous suspension was injected for a period of 3 weeks at a dose level of 5 mg.
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daily. The treatment was started after the tumours had reached an initial size
ranging from 0-6 to 1.4 square inches. All tumours reached a size of 3-0 square
inches before the treatment period was completed. There was no difference in
the mean growth periods of treated and control groups. Cortisone treatment
caused considerable body weight loss, showing again that body growth depres-
sion need not slow the growth oftransplanted fibroadenomata. Cortisone treated
rats were not killed for 4 or more weeks after injections were discontinued. The
tumours showed a norma] morphology at this time.
(5) Effect of anterior pituitary preparations.
Three pituitary preparations were tested for their effect on the growth and
morphology of the transplanted fibroadenoma. These were:
(1) a bovine anterior pituitary saline suspension;
(2) a sheep pituitary extract;
(3) a biologically pure growth hormone preparation obtained from Armour
Laboratories Inc.
(1) The anterior lobes were dissected from frozen whole beef pituitaries.
The required amount of anterior pituitary substance was weighed, ground with
sand in a mortar and mixed with physiological saline in the proportions of 1 g.
of anterior pituitary to 5 mi. ofphysiological saline. This was mixed well, centri-
fuged and the supernatant plus the fine sediment at the top ofthe residue taken off
and refrigerated. No more than a week's supply was prepared at one time.
This material was injected subcutaneously in doses of 0.5 ml. daily or 1.0 ml.
every second day, this being equivalent to 100 and 200 mg. respectively ofanterior
pituitary substance.
Biological assays have indicated the presence ofgrowth hormone andprolactin
but little gonadotrophic activity in this preparation.
(2) A sheep pituitary extract was prepared in this laboratory over 15 years
ago with the purpose of obtaining prolactin. No details, however, are available
for the method ofextraction. The product was a crude one and it was considered
that potentially it contained the activity of manyofthe pituitary hormones. Bio-
logical essays indicated that there was prolactin but no growth hormone activity
in the extract. Gonadotrophic activity was not determined. The material was
injected subcutaneously in a neutralized water suspension at a dose level of
25 mg. daily.
(3) The growth hormone was a water soluble product which, although not
chemically pure, wasreported to be free ofall other biologically active components
of the pituitary. Daily doses of 0.5 mg. were administered in water solution by
subcutaneous injection.
The beef anterior pituitary preparation was administered to female, mnale,
and ovariectomized female rats (Series F5-C, F6, F8, Fll and 4F-3). In addition,
female castrates and males were treated with both the anterior pituitary and di-
ethylstilbestrol (5 j/tg. daily or 10 /jg. every second day), (Series F6 and F9-B).
The sheep pituitary extract and the growth hormone were tested in single experi-
ments with female rats (Series F9-A and F-12). Representative results are given
in Table VI
Both beef anterior pituitary and sheep pituitary preparations stimulated
the growth ofthe fibroadenomata. The former was active in males and castrated
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TABLE VII.-Effect of Various Pituitary Preparations on the Growth of Transplanted
Fibroadenomata in Rats.
Treatment.*
A.P.S.,t limited
Controls, intact
Ovariectomy + A.P.S., limited
Ovariectomy + (A.P.S. and Stilbestrol),
limited
Ovariectomized controls
111 . A.P.S., continuous
Controls, intact
Ovariectomy + A.P.S., continuous.
Ovariectomized controls
F8 A.P.S., continuous
Controls
F)-B A.P.S., continuous
A.P.S. + stilbestrol, continuous
Controls
F9-A Sheep pituitary extract, continuous
Controls
Fl 2 . Growth Hormone, continuous
Controls
Number Numnber
of of
Sex. rats. takes.
F 8 . 8
F . 10 9
Mean latent Mean growth
period period
(days). (days).
22± 1.1 21± 1.01
43+15-4 35± 3*2
F 8 . 8 . 24+ 1-0 23+ 1-9T
F 8 . 21+ 1.2L! . 27± 1.41
F 8 . 7 29± 2-9 37± 1-6
. F 10 5 46± 22 . 43± 7-1
...F 10 7 . 61 ± 6-2 56±21-9
F 10 5 56± 5-7 . 59±15-1
F . 10 0 - -
MI 10 9 . 38 2 2 2 . 26 + 2-0l
M . 10 . 10 45± 3-4 . 32± 1-6
M
M
M
10
10
10
4
8
0
80i14-6 32± 3-2
69± 4-6 78±13-6
F . 10 8 . 34+ 1-7 . 29± 08
F 10 . 7 . 41- 3-6 . 35± 2-0
F 10 8 . 484- 51- . 43± 9- 7
F 10 . 7 . 42± 6-1 . 39± 3-9
* Treatment, for dose levels see description in text.
t A.P.S., beef anterior pituitary suspension.
P < 0 01, treated versus controls.
1 P < 0 05, treated versus controls.
females as well as in intact females. During the course ofsome ofthe experiments
using the beef anterior pituitary mixture, penicillin was administered for a short
period to allay infection induced by the injected material. This treatment
proved to be satisfactory and did not appear to influence the tumour growth.
The action of beef anterior pituitary was not evident in all experiments with
intact females (Series F9-B and Fll). In these cases, however, the individual
variation was extreme inr both control and treated animals, a condition which
mnay have masked anyexisting response. Stilbestrol didnot appearto augment the
anterior pituitary stimulation of fibroadenomata in castrated females or in males.
In the single experiment conducted, there was no evidence of a response to
pure growth hormone.
There was no change in the morphology ofthe benign tumours or the incidence
of fibrosarcomata with any of the treatment regimes given.
DISCUSSION.
Although the fibroadenoma is more successfully propagated in the female host,
estrogen administered in small doses to intact rats caused no change in tumour
growth or morphology, except in one early experiment (F3). This one exception
may be attributed to chance variation or can be interpreted as evidence of a greater
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responsiveness in early tumour generations. This possibility is supported by the
findings of Heiman and Mohs, which were reviewed earlier, but is not upheld by
the later work using third generation tumours ofLines 3F and 4F.
In male rats, however, small amounts of exogenous estrogen produced tumour
growth and morphology comparable to that of female controls. This response
supplies further proof for the need of minimal estrogen levels for maximum
growth of the mammary fibroadenoma in rats. Depression of the male sex
hormone may also be a factor involved, particularly with regard to the increased
epithelial development of tumours in estrogen treated males. The inhibition of
tumour epithelium by testosterone was postulated in the preceding paper
(Millar and Noble, 1954), when it was observed that tumours were more fibrous in
male rats than in female controls, but were unchanged morphologically in cas-
trated females. Experiments with administered androgens tend to support this
contention. Mohs (1941) reported that prolonged injections of small doses of
testosterone brought about a progressive loss of tumour epithelium but no change
in growth rate. Using a higher dose level and shorter treatment period, in this
laboratory the tumours tended to be more fibrous and showed only slight growth
inhibition. Heiman (1940a and 1943) reported a similar but more dramatic
response to the action of testosterone on both growth rate and epithelial develop-
ment. Dose levels, not clearly defined, were probably intermediate to those used
by Mohs (1941) and those used in this laboratory. High susceptibility to change
seems typical ofthe tumours studied by this worker. This may be a characteristic
of the strain of rat used, for the Sprague-Dawley strain employed by us was also
used by Mohs.
The negative response of fibroadenomata to administered progesterone re-
ported herein, as opposed to the marked inhibition observed by Heiman (1940a
and 1943) offers another example of varied susceptibility. Although in our
experiments, progesterone treatment was for the 4-week period only, the relatively
undramatic effect of large doses of testosterone in intact females makes a marked
response to progesterone rather difficult to envision even if the treatment period
had been prolonged.
Inhibition of the growth of transplanted mammary fibroadenomata produced
by high doses ofestrogen has not been reported by other workers. To the authors'
knowledge Emge (1939) is the only worker to use similar high levels of estrogens
in studies on mammary fibroadenomata. His experiments were designed to study
the effect ofsuch treatment on the incidence ofcarcinoma in these benign tumours.
Marked epithelial hyperplasia, but no evidence of carcinomatous transformation
was observed. It is assumed that the treatment occurred after tumour growth-
initiation. No reference is made to alterations in tuinour growth rate. A system-
atic study of changes in tumour morphology during treatment has not been car-
ried out in this laboratory, but examination oftumours from a few rats which died
during treatment periods, gave no indication ofthe pronounced epithelial response
observed by Emge (1939). This again demonstrates the limited capacity of the
epithelium of the tumours observed by us to respond to environmental changes
without the physiological range.
Considerable speculation could be devoted to the mode of action of stilbestrol
on the growth of fibroadenomata. The most obvious possibility, i.e., that of a
nonspecific reflection of body growth depression, has been ruled out by paired
feeding experiments. The fibroadenoma may be responding like normal immature
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mammary tissue, for it has been shown that mammary gland development in
young rats is depressed by large doses of estrogen (Astwood, Geschickter and
Rausch, 1937). It is well known that excessive estrogen will inhibit the growth of
some malignant neoplasms in rats and mice (Eisen, 1941; Nathanson and Salter,
1939) and in humans such action is well exemplified by the use ofestrogen therapy
for breast cancer. The variability ofresponse in humans (Nathanson and Kelley,
1952) brings to mind the all or none response obtained with stilbestrol administra-
tion to rats bearing growing fibroadenomata. It is difficult to assess to what
extent the benign fibroadenoma can be compared with malignant growths or to
normaltissuewithregardto themechanismofresponsetoestrogenexcesses. Never-
theless, the hormonal imbalance created, with the resulting depression ofanterior
pituitary function, very likely plays an important part in the inhibition of the
benign fibroadenoma in other types of breast tumours and as well in normal
breast tissue.
From a therapeutic point of view the desirability of such a response in the
fibroadenoma is questionable, since the incidence of malignant transformations
was increased in the groups treated during tumour growth, this event being
coincident with tumour growth inhibition. In the preceding paper (Millar and
Noble, 1954) it was shown that the change to fibrosarcoma was restricted to slow
growing fibroadenomata and it was proposed that the fibrosarcomatous trans-
formation was instigated in an effort to overcome the action of some intrinsic
inhibitory agent. Apparently, contradictory to this theory, was the lack of an
increased incidence of fibrosarcomata in the tumours of rats injected with high
doses of stilbestrol from the time of tumour implantation, where artificially pro-
longed latent periods of over 200 days were observed. In view of this more
dramatic growth response it is difficult to understand why stilbestrol administra-
tion during tumours growth should increase the incidence of fibrosarcomata.
Possibly the treatment or the resulting growth inhibition is more effective in
bringing about a fibrosarcomatous transformation in established tumours which
have been actively growing than in the temporarily dormant implant.
The findings reported for the action of anterior pituitary preparations on the
mammary fibroadenoma are ofparticular interest in view ofthe currently increas-
ing evidence of the part played by pituitary hormones in carcinogenesis (Moon,
Simpson, Li and Evans, 1950; Moon, Simpson and Evans, 1952; Noble and
Walters, 1954).
The identity of the pituitary component or components which stimulate the
growth ofthe fibroadenoma is not known. Since both the beefand sheep pituitary
preparations used were crude products, the response was probably a result of the
integrated action of several pituitary hormones. However, if a single hormone
was responsible for the increased tumour growth rates observed, prolactin would
seem to be the most likely possibility. Gonadotrophic activity was low in the
beefpituitary preparation, as was growth hormone activity in the sheep pituitary
extract. Negative results with purified growth hormone further justifies its
elimination. Prolactin activity was high in both crude preparations. Adreno-
corticotrophin and thyrotrophin were probably present and cannot be eliminated
as possible active factors, but one is inclined to favour prolactin in view of its
important role in mammary tissue development and lactation (Folley, 1952).
The lack of response to purified growth hormone confirms the findings of Hei-
man and Krehbiel (1936). However, no synergism was noted between estrogen
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and the beef anterior pituitary preparation, while these workers reported that
estrogen plus gonadotrophin or growth hormone stimulated tumour growth
although none ofthe individual products were active in intact rats.
In conclusion, areviewofthe findingsreportedhereinandelsewhere leads to the
realizationthatinthe mammary fibroadenoma one is dealingwith a tissue possess-
ingbothnormalandneoplasticproperties. Beingofmammaryoriginthesetumours
frequently respond to hormones involved in mammary gland development, but
the type and degree ofresponse often differs widely from that expected of normal
tissue. Thus, testosterone which stimulates alveolar development in mammary
tissue, depresses the epithelium of transplanted fibroadenomata. Alternately,
estrogen at physiological levels which normally stimulate epithelial development
alone promotes the growth of these predominantly connective tissue tumours.
Estrogen excesses may or may not increase glandular tissue in these tumours, the
variation between tumour lines and strains of rats being marked in this respect.
Finally, cortisone which causes the breakdown of some collagen connective
tissues, is ineffective in altering the growth characteristics of the mammary
fibroadenoma.
SUMMARY.
1. The administration of small doses of diethylstilbestrol to female rats did
not alter the growth characteristics or morphology of transplanted mammary
fibroadenomata. However, tumour growth rate and epithelial development in
similarly treated male rats was increased to equal that of female controls.
2. High levels of diethylstilbestrol (100-200 tg. daily) prevented tumour
growth initiation when administered from the time of tumour implantation.
If treatment was commenced after tumour growth initiation, the response was
less uniform, but if any, was one of growth retardation or arrest. The incidence
of fibrosarcomata was increased in the latter group and this event was restricted
to the fibroadenomata showing slowed or arrested growth.
3. Testosterone proprionate produced slight tumour growth inhibition and an
indication of depressed tumour epithelial development. Experimental findings
were inconclusive but the results ofothers support the trends observed.
4. Progesterone and cortisone in the amounts and for the duration adminis-
tered did not alter the growth rate or morphology oftransplanted fibroadenomata
in female rats.
5. Crude beef and sheep pituitary preparations stimulated tumour growth in
intact female rats. The former was also active in males and castrated females.
The simultaneous administration of small doses of estrogen did not augment
the action ofthe beef pituitary preparation. Biologically pure growth hormone
did not alter the growth or morphology of the transplanted fibroadenomata in
female rats.
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